This Week's Herman Trend Alert

Nail-Painting Robot Coming
to a Salon Near You

 

  The Herman Trend Alert

January 4, 2023

What Cancer and Diabetes Have in Common

I never thought about the fact that cancer and diabetes had anything in common. To me, they always seemed like they are very different diseases. So, what attribute do they share? In one of her videos, Dr. Denise Faustman talks about the fact that in Type 1 Diabetes (T1D), the immune system goes into overdrive and attacks the body. That is why the Diabetes is described as an "autoimmune disease." On the other hand, the immune system virtually ignores cancer cells; that is why they proliferate unhindered. Interesting, right? The Faustman Lab at Mass General Hospital in Boston, Massachusetts, has identified a key family of immune cells responsible for regulating the immune response.

Decades of Research
Back in 2014, I wrote about Faustman's promising breakthrough in T1D treatment, and perhaps reverse it altogether. At that time, Dr. Faustman at the Massachusetts General Hospital Immunobiology Lab was conducting research to develop a curative therapy for this autoimmune disease. At that time approximately 80 people per day were diagnosed with T1D. That was 15,000 adults and 15,000 children every year who were diagnosed. Now, the figure is even higher. At that time, Faustman was testing the efficacy of a century old vaccine Bacillus Calmette-Guerin (BCG), used for the prevention of tuberculosis, then (and now) testing it in the treatment and possible immune reversal of T1D.

Human Trials Proceed
Unfortunately, human trials take time. The good news is that the diverse clinical trials in both type 1 diabetes and multiple sclerosis, administration of the BCG vaccine to diseased adults has shown great promise. In a Phase I trial in advanced type 1 diabetes (mean duration of diabetes 15 years), 2 BCG vaccinations spaced 4 weeks apart selectively eliminated autoreactive regulatory T-cells, induced beneficial immune cells called Tregs, and allowed for a transient and small restoration of insulin production. The advancing global clinical trials using BCG combined with other data on BCGs induction of T-cells suggest value in this generic drug and possible immune reversal of the T1D autoimmune process.

An Update of Dr. Denise Faustman's Type 1 Diabetes Research
More recently. the Faustman Lab showed that BCG boosts a cytokine, an immune system protein called TNF, which is beneficial in autoimmune diseases by directly eliminating the autoreactive T-cells that attack the pancreas, as well as by inducing Tregs.

Cancer Research
In cancer, the immune system is tricked into not attacking the cancerous cells. The Faustman lab has identified a kind of regulatory immune cells essential to turning the immune system back on. This breakthrough has led to the generation of a new class of antibodies specific to the tumor immediate environment.

The Future of this Research
Once BCG is determined to work for T1D, Faustman intends to look at its application to other autoimmune diseases; already she has expanded her research to include Multiple Scleroses. My expectation is that these breakthroughs are only the beginning. We can hope that with advancing technology, the developments may come faster.

Next Week's Herman Trend Alert: Valid Research or Misinformation?
Everybody knows, you can't trust everything you read on the web. But, how do you determine what is real and what is not, what is valid research and what is prejudiced by a conflict of interest. If you have been as challenged as I have, you will appreciate this inquiry into evaluation of source information. I know that many of you depend on the Herman Trend Alert to deliver facts, information, and insights. I take this responsibility very seriously. And by the way, Happy New Year and thank you for your loyalty.


© Copyright 1998- by The Herman Group, Inc. -- reproduction for publication is encouraged, with the following attribution: From "The Herman Trend Alert," by Joyce Gioia, Strategic Business Futurist. 1.336.210.3548 or https://hermangroup.com. To sign up, visit https://HermanTrendAlert.com. The Herman Trend Alert is a trademark of The Herman Group, Inc."

HEAR JOYCE SPEAK TOMORROW AT 11:30 AM EDT
Tomorrow morning, Joyce will be a Fireside Chat Speakers at the Brightside Business Women Empowerment Virtual Conference where she will talk about how business women can use the insights from her new, groundbreaking book, EXPERIENCE RULES, to be successful. Register for FREE at https://brightsideglobaltrade.org/women.

GET COACHING FOR YOUR PEOPLE FOR LESS THAN $1/DAY!
Gain access to dozens of coaches for the same low price. Find out more by visiting https://ingomu.com/joyceg

JOYCE IS ON THE RADIO EVERYDAY NOW
To listen to Joyce's TV shows on the radio, simply visit RadioFutures.com. Joyce's show is streaming every day at 3:00PM Pacific Time.

To read this Herman Trend Alert on the web: https://hermangroup.com/alert/archive_3-29-2023.html.


Herman Trend Alerts are produced by the Herman Group, strategic business futurists, Certified Management Consultants, authors, and professional speakers.

New subscribers are always welcome. There is no charge for this public service. The Herman Trend Alert is read by over 30,000 people in 90 countries, including other websites and printed periodicals. Click here to sign up for the Herman Trend Alert.

Do you enjoy receiving this weekly e-mail update? Contact us about our co-branded Herman Trend Alert service.


Subscribe or Unsubscribe to weekly Herman Trend Alert
View this week's Herman Trend Alert
Archived Weekly Herman Trend Alerts

                                                                                                                                                                                                                                                                                                                                                                         


[ Home · About · Products · Resources · Media ]

 

7112 Viridian Lane
Austin, TX 78739
Voice: 336-210-3548
Toll Free in US & Canada: 800-227-3566
E-mail: info@hermangroup.com


  © The Herman Group. All rights reserved.

Web site design by WebEditor Design Services, Inc.